Conditions: Hepatic Insufficiency
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.

Detailed description:

Arms:
arm 1: Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function arm 2: Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment arm 3: Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment arm 4: Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment

Interventions: intervention 1: Evacetrapib
Intervention descriptions: intervention 1: None

Protocol document: